Literature DB >> 20599767

Dexamethasone transcriptionally increases the expression of the pregnane X receptor and synergistically enhances pyrethroid esfenvalerate in the induction of cytochrome P450 3A23.

Deshi Shi1, Dongfang Yang, Bingfang Yan.   

Abstract

The pregnane X receptor (PXR) is recognized as a key regulator for the induction of a large number of genes in drug metabolism and transport. The transactivation of PXR is enhanced by the glucocorticoid dexamethasone and the enhancement is linked to the induction of PXR in humans and rats. The present study was undertaken to determine the mechanism for the induction and ascertain the synergistic effect on the expression of CYP3A23, a rat PXR target. In primary hepatocytes, significant induction of PXR was detected as early as 2h after the treatment and the maximal induction occurred at 1 microM dexamethasone. Similar induction kinetics was observed in the hepatoma line H4-II-E-C3. The induction was abolished by actinomycin D and dexamethasone efficaciously stimulated the rat PXR promoter. In addition, dexamethasone synergized esfenvalerate (an insecticide and a PXR activator) in inducing CYP3A23 and stimulating the CYP3A23 promoter. The full promoter of CYP3A23 (-1445/+74) was activated in a similar pattern as the changes in PXR mRNA in response to dexamethasone, esfenvalerate and co-treatment. In contrast, different responding patterns were detected on the stimulation of the CYP3A23 proximal promoter. Synergistic stimulation was also observed on the CYP3A4-DP-Luc reporter, the human counterpart of CYP3A23. These findings establish that transactivation is responsible for the induction of rat PXR and the induction presents potential interactions with insecticides in a species-conserved manner. The different responding patterns among CYP3A23 reporters point to an involvement of multiple transcriptional events in the regulation of CYP3A23 expression by dexamethasone, esfenvalerate and both. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20599767      PMCID: PMC2933965          DOI: 10.1016/j.bcp.2010.06.043

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  46 in total

1.  Guideline to reference gene selection for quantitative real-time PCR.

Authors:  Aleksandar Radonić; Stefanie Thulke; Ian M Mackay; Olfert Landt; Wolfgang Siegert; Andreas Nitsche
Journal:  Biochem Biophys Res Commun       Date:  2004-01-23       Impact factor: 3.575

2.  Mouse liver and kidney carboxylesterase (M-LK) rapidly hydrolyzes antitumor prodrug irinotecan and the N-terminal three quarter sequence determines substrate selectivity.

Authors:  Mingxing Xie; Dongfang Yang; Micheal Wu; Bob Xue; Bingfang Yan
Journal:  Drug Metab Dispos       Date:  2003-01       Impact factor: 3.922

Review 3.  Mechanisms of selective action of pyrethroid insecticides.

Authors:  J E Casida; D W Gammon; A H Glickman; L J Lawrence
Journal:  Annu Rev Pharmacol Toxicol       Date:  1983       Impact factor: 13.820

4.  2.1 A crystal structure of human PXR in complex with the St. John's wort compound hyperforin.

Authors:  Ryan E Watkins; Jodi M Maglich; Linda B Moore; G Bruce Wisely; Schroeder M Noble; Paula R Davis-Searles; Mill H Lambert; Steven A Kliewer; Matthew R Redinbo
Journal:  Biochemistry       Date:  2003-02-18       Impact factor: 3.162

5.  Lipopolysaccharide and cecal ligation/puncture differentially affect the subcellular distribution of the pregnane X receptor but consistently cause suppression of its target genes CYP3A.

Authors:  Karuna Sachdeva; Bingfang Yan; Clinton O Chichester
Journal:  Shock       Date:  2003-05       Impact factor: 3.454

6.  Glucocorticoid receptor enhancement of pregnane X receptor-mediated CYP2B6 regulation in primary human hepatocytes.

Authors:  Hongbing Wang; Stephanie R Faucette; Darryl Gilbert; Summer L Jolley; Tatsuya Sueyoshi; Masahiko Negishi; Edward L LeCluyse
Journal:  Drug Metab Dispos       Date:  2003-05       Impact factor: 3.922

7.  The pregnane X receptor binds to response elements in a genomic context-dependent manner, and PXR activator rifampicin selectively alters the binding among target genes.

Authors:  Xiulong Song; Mingxing Xie; He Zhang; Yuxin Li; Karuna Sachdeva; Bingfang Yan
Journal:  Drug Metab Dispos       Date:  2004-01       Impact factor: 3.922

8.  A glucocorticoid response element in the LTR U3 region of Friend murine leukaemia virus variant FIS-2 enhances virus production in vitro and is a major determinant for sex differences in susceptibility to FIS-2 infection in vivo.

Authors:  Torunn Bruland; Liss Anne S Lavik; Hong Yan Dai; Are Dalen
Journal:  J Gen Virol       Date:  2003-04       Impact factor: 3.891

9.  Effect of pretreatment of cytochrome P450 (P450) modifiers on neurobehavioral toxicity induced by deltamethrin.

Authors:  M Dayal; D Parmar; A Dhawan; Mohd Ali; U N Dwivedi; P K Seth
Journal:  Food Chem Toxicol       Date:  2003-03       Impact factor: 6.023

10.  Coactivator binding promotes the specific interaction between ligand and the pregnane X receptor.

Authors:  Ryan E Watkins; Paula R Davis-Searles; Mill H Lambert; Matthew R Redinbo
Journal:  J Mol Biol       Date:  2003-08-22       Impact factor: 5.469

View more
  17 in total

Review 1.  Pregnane X receptor and drug-induced liver injury.

Authors:  Yue-Ming Wang; Sergio C Chai; Christopher T Brewer; Taosheng Chen
Journal:  Expert Opin Drug Metab Toxicol       Date:  2014-09-25       Impact factor: 4.481

2.  MicroRNA-30c-1-3p is a silencer of the pregnane X receptor by targeting the 3'-untranslated region and alters the expression of its target gene cytochrome P450 3A4.

Authors:  Thaveechai Vachirayonstien; Bingfang Yan
Journal:  Biochim Biophys Acta       Date:  2016-04-13

3.  Hypolipidemic agent Z-guggulsterone: metabolism interplays with induction of carboxylesterase and bile salt export pump.

Authors:  Dongfang Yang; Jian Yang; Deshi Shi; Da Xiao; Yi-Tzai Chen; Chris Black; Ruitang Deng; Bingfang Yan
Journal:  J Lipid Res       Date:  2012-01-14       Impact factor: 5.922

4.  Nuclear Receptors in Drug Metabolism, Drug Response and Drug Interactions.

Authors:  Chandra Prakash; Baltazar Zuniga; Chung Seog Song; Shoulei Jiang; Jodie Cropper; Sulgi Park; Bandana Chatterjee
Journal:  Nucl Receptor Res       Date:  2015

5.  A comparative study of hollow copper sulfide nanoparticles and hollow gold nanospheres on degradability and toxicity.

Authors:  Liangran Guo; Irene Panderi; Daisy D Yan; Kevin Szulak; Yajuan Li; Yi-Tzai Chen; Hang Ma; Daniel B Niesen; Navindra Seeram; Aftab Ahmed; Bingfang Yan; Dionysios Pantazatos; Wei Lu
Journal:  ACS Nano       Date:  2013-10-01       Impact factor: 15.881

Review 6.  Role of CAR and PXR in xenobiotic sensing and metabolism.

Authors:  Yue-Ming Wang; Su Sien Ong; Sergio C Chai; Taosheng Chen
Journal:  Expert Opin Drug Metab Toxicol       Date:  2012-05-03       Impact factor: 4.481

7.  Glucocorticoid exposure induces preeclampsia via dampening 1,25-dihydroxyvitamin D3.

Authors:  Dongxin Zhang; Ji Zeng; Xili Miao; Haojing Liu; Liangfang Ge; Wei Huang; Jinyu Jiao; Duyun Ye
Journal:  Hypertens Res       Date:  2017-11-02       Impact factor: 3.872

8.  Role of pregnane X receptor and aryl hydrocarbon receptor in transcriptional regulation of pxr, CYP2, and CYP3 genes in developing zebrafish.

Authors:  Akira Kubota; Jared V Goldstone; Benjamin Lemaire; Matthew Takata; Bruce R Woodin; John J Stegeman
Journal:  Toxicol Sci       Date:  2014-11-25       Impact factor: 4.849

9.  Regulation of carboxylesterase-2 expression by p53 family proteins and enhanced anti-cancer activities among 5-fluorouracil, irinotecan and doxazolidine prodrug.

Authors:  Da Xiao; Dongfang Yang; Liangran Guo; Wei Lu; Margaret Charpentier; Bingfang Yan
Journal:  Br J Pharmacol       Date:  2013-04       Impact factor: 8.739

Review 10.  Xenobiotic-sensing nuclear receptors involved in drug metabolism: a structural perspective.

Authors:  Bret D Wallace; Matthew R Redinbo
Journal:  Drug Metab Rev       Date:  2012-12-05       Impact factor: 4.518

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.